Mitochondrial Myopathy Cell Models for Research

Mitochondrial myopathies are a clinically and genetically heterogeneous group of disorders caused by impaired oxidative phosphorylation (OXPHOS) in skeletal muscle. According to Orphanet and WHO estimates, the minimum prevalence of mitochondrial diseases is approximately 1 in 5,000 live births, with mitochondrial myopathies representing a significant subset. The incidence of primary mitochondrial disorders is estimated at 1 in 2,000 to 1 in 5,000 in the general population. Key risk factors include inherited pathogenic variants in mitochondrial DNA (mtDNA) or nuclear DNA (nDNA) genes, maternal inheritance patterns for mtDNA mutations, and de novo mutations. Clinical impact includes progressive muscle weakness, exercise intolerance, ophthalmoplegia, and multisystem involvement (encephalopathy, cardiomyopathy, neuropathy). There is no curative treatment; management is supportive. Five-year survival varies widely by genotype and phenotype; for example, patients with the m.3243A>G mutation (MELAS) have a 5-year survival of approximately 60-80% after diagnosis, while those with infantile-onset Leigh syndrome due to SURF1 mutations have a much poorer prognosis, with mortality often exceeding 50% within the first 5 years. Data from the North American Mitochondrial Disease Consortium (NAMDC) and the Mitochondrial Disease Sequence Data Resource (MSeqDR) provide ongoing epidemiological insights.

Mitochondrial myopathies are ideal for mechanistic studies because they bridge genetic, biochemical, and metabolic pathways. Subtypes include MELAS (m.3243A>G in MT-TL1), MERRF (m.8344A>G in MT-TK), Kearns-Sayre syndrome (large-scale mtDNA deletions), and nuclear gene disorders such as SURF1-related Leigh syndrome, POLG-related disorders, and TK2 deficiency. Public datasets such as ClinVar, MITOMAP, and the NCBI Gene database catalog pathogenic variants. Open questions include: how heteroplasmy thresholds determine phenotype, the role of mitochondrial dynamics (fusion/fission) in disease progression, and the interplay between mtDNA mutations and nuclear gene modifiers. The ability to generate isogenic cell models with defined mtDNA variants or nuclear gene knockouts enables precise dissection of these mechanisms.

Mitochondrial myopathies are not classified as carcinogenic, but the molecular pathways disrupted are central to cellular energetics and survival. Key pathways include:

• • OXPHOS deficiency:

1. Impaired electron transport chain (ETC) complexes I, III, IV, and V reduce ATP production.

2. Increased reactive oxygen species (ROS) production from complex I and III.

3. Activation of AMPK and mTORC1 signaling in response to energy stress.

• • Mitochondrial quality control:

1. Defective mitophagy (PINK1/Parkin pathway) leads to accumulation of damaged mitochondria.

2. Altered mitochondrial dynamics (OPA1, MFN1/2, DRP1) affect fusion and fission balance.

• • Apoptosis and cell death:

1. Release of cytochrome c and SMAC/DIABLO from damaged mitochondria.

2. Activation of intrinsic caspase cascade.

• • Secondary metabolic reprogramming:

1. Shift toward glycolysis (Warburg-like effect) in affected muscle fibers.

2. Accumulation of lactate and TCA cycle intermediates.

The table below summarizes common genetic alterations in mitochondrial myopathies, compiled from ClinVar, MITOMAP, and published cohorts. Frequencies are approximate and vary by population.

Data sources: ClinVar, MITOMAP, NCBI Gene, and published cohort studies (e.g., NAMDC).

Key signaling networks deregulated in mitochondrial myopathy include:

• • AMPK pathway:
• • Activated by increased AMP/ATP ratio.
• • Promotes catabolic processes (autophagy, fatty acid oxidation).
• • Chronic activation can lead to muscle atrophy.
• • mTORC1 pathway:
• • Inhibited by AMPK and energy stress.
• • Reduced protein synthesis and mitochondrial biogenesis.
• • Dysregulation contributes to muscle weakness.
• • PGC-1alpha network:
• • Master regulator of mitochondrial biogenesis.
• • Downregulated in mitochondrial myopathy.
• • Impaired response to exercise and oxidative stress.
• • Sirtuin (SIRT1/3) signaling:
• • NAD+-dependent deacetylases.
• • Modulate mitochondrial function and stress response.
• • Altered NAD+ metabolism in mitochondrial disease.
• • Integrated stress response (ISR):
• • Activation of ATF4, CHOP, and GCN2.
• • Contributes to muscle fiber degeneration.
• • Inflammatory signaling:
• • Activation of NF-kB and NLRP3 inflammasome.
• • Chronic inflammation in affected muscle.

Common cell models for mitochondrial myopathy research include patient-derived fibroblasts, cybrids (transmitochondrial cybrids), and induced pluripotent stem cell (iPSC)-derived myoblasts. The table below lists representative cell lines and their key mutations.

Organoids: 3D skeletal muscle organoids derived from patient iPSCs are emerging as powerful models that recapitulate muscle architecture, contractility, and metabolic defects. They offer advantages over 2D cultures by maintaining cell-cell and cell-matrix interactions, and they can be used for drug screening and functional genomics.

Animal models for mitochondrial myopathy include:

• • Genetically engineered mouse models (GEMMs):
• • mtDNA mutator mice (Polg D257A) exhibit premature aging and mitochondrial dysfunction.
• • SURF1 knockout mice show complex IV deficiency and Leigh-like syndrome.
• • TK2 knockout mice develop mtDNA depletion and myopathy.
• • Transgenic mice expressing mutant mtDNA (e.g., m.3243A>G) via pronuclear injection.
• • Induced models:
• • Pharmacological inhibition of OXPHOS (e.g., rotenone, antimycin A) in rodents.
• • Exercise-induced stress models.
• • Patient-derived xenografts (PDX):
• • Not commonly used for mitochondrial myopathy due to the genetic nature of the disease, but PDX of patient tumors with mtDNA mutations can inform cancer metabolism.
• • Non-mammalian models:
• • Zebrafish with mtDNA mutations.
• • Drosophila with ETC gene knockdown.
• • C. elegans with mitochondrial gene mutations.

CRISPR-Cas9 and related technologies enable the generation of isogenic cell lines with precise mitochondrial or nuclear gene edits. Examples include:

• • MT-TL1 m.3243A>G knock-in in 143B cybrids: introduces the MELAS mutation into a controlled mtDNA background.
• • MT-ND4 knockout in HeLa cells: creates complex I deficiency for studying ROS production.
• • SURF1 knockout in HEK293T: models Leigh syndrome with complex IV deficiency.
• • POLG knockout in human fibroblasts: induces mtDNA depletion and replication stress.
• • TFAM knockout in mouse myoblasts: disrupts mtDNA packaging and transcription.

Commercially available, sequence-verified gene-edited cell models (e.g., knockout, knock-in, reporter lines) accelerate research by providing reproducible, validated tools. These models are engineered using CRISPR and are quality-controlled for genomic integrity and functional outcomes. They enable researchers to study disease mechanisms, perform drug screens, and validate targets without the variability of patient-derived cells.

Knockout and knock-in cell lines allow systematic validation of gene function. For example:

• • SURF1 knockout HEK293T cells confirm the role of SURF1 in cytochrome c oxidase assembly.
• • MT-TL1 mutant cybrids demonstrate impaired mitochondrial translation and respiratory chain deficiency.
• • POLG knockout fibroblasts show mtDNA depletion and increased sensitivity to nucleoside analogs.
• • CRISPR screens in mitochondrial myopathy models identify modifier genes that influence disease severity.

These models enable high-throughput functional genomics to uncover synthetic lethal interactions and compensatory pathways.

Isogenic pairs (wild-type vs. mutant) are powerful for drug screening. For example:

• • Screening compounds that rescue OXPHOS deficiency in SURF1 knockout cells.
• • Testing drugs that modulate mtDNA heteroplasmy in MT-TL1 mutant cybrids.
• • Identifying resistance mechanisms to mitochondrial-targeted therapies.
• • High-throughput screens with reporter cell lines (e.g., ATP biosensors) to measure metabolic rescue.

These applications are critical for developing precision medicine approaches for mitochondrial myopathies.

CRISPR-based synthetic lethality screens in mitochondrial myopathy cell models can identify biomarkers of disease progression and therapeutic response. For example:

• • Genome-wide knockout screens in MT-ND4 mutant cells reveal genes essential for survival under complex I deficiency.
• • Proteomic and metabolomic profiling of isogenic lines identifies candidate biomarkers (e.g., FGF21, GDF15) that are elevated in mitochondrial disease.
• • Reporter lines with fluorescent tags for mitochondrial membrane potential or ROS enable live-cell biomarker discovery.

These approaches accelerate the translation of basic findings into clinical assays.

The following databases provide valuable data for mitochondrial myopathy research.

These resources support target identification, variant interpretation, and model validation.